Clinical Effects of Escitalopram Combined with Dopasin on Patients with Parkinson’s Disease and its Effects on Inflammatory Factors

HU Qiao; XIANG Mingqing; GUO Caihua; WANG Hua

doi:10.14009/j.issn.1672-2124.2021.01.011

您当前的位置：

首页 >

文章列表页 >

Clinical Effects of Escitalopram Combined with Dopasin on Patients with Parkinson’s Disease and its Effects on Inflammatory Factors

更新时间：2022-10-08

- Clinical Effects of Escitalopram Combined with Dopasin on Patients with Parkinson’s Disease and its Effects on Inflammatory Factors
- Vol. 21, Issue 1, Pages: 41-44(2021)
- 作者机构：
  
  荆州市第一人民医院神经内科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.01.011
  CLC： R742.5
- Published：2021，
扫描看全文
[1]胡乔,向明清,郭才华,汪华.艾司西酞普兰联合多巴丝肼治疗帕金森病的临床效果及对炎症因子的影响[J].中国医院用药评价与分析,2021,21(01):41-44.

HU Qiao, XIANG Mingqing, GUO Caihua, et al. Clinical Effects of Escitalopram Combined with Dopasin on Patients with Parkinson’s Disease and its Effects on Inflammatory Factors. [J]. 21(1):41-44(2021)
[1]胡乔,向明清,郭才华,汪华.艾司西酞普兰联合多巴丝肼治疗帕金森病的临床效果及对炎症因子的影响[J].中国医院用药评价与分析,2021,21(01):41-44. DOI： 10.14009/j.issn.1672-2124.2021.01.011.

HU Qiao, XIANG Mingqing, GUO Caihua, et al. Clinical Effects of Escitalopram Combined with Dopasin on Patients with Parkinson’s Disease and its Effects on Inflammatory Factors. [J]. 21(1):41-44(2021) DOI： 10.14009/j.issn.1672-2124.2021.01.011.

摘要

目的:探讨艾司西酞普兰联合多巴丝肼治疗帕金森病的临床效果及对炎症因子的影响。方法:选取2018年4月至2019年12月荆州市第一人民医院收治的帕金森病患者138例

采用完全随机数法分为对照组和观察组

每组69例。对照组患者给予多巴丝肼治疗

观察组患者在对照组的基础上联合艾司西酞普兰治疗。观察两组患者汉密尔顿抑郁量表（Hamilton depression scale

HAMD）、统一帕金森病评分量表（unified Parkinson’s disease rating scale

UPDRS）、汉密尔顿焦虑量表（Hamilton anxiety scale

HAMA）及韦氏记忆量表（Wechsler memory Scale

WMS）评分

炎症因子水平、临床疗效及不良反应发生情况。结果:治疗后

观察组患者的HAMD、UPDRS和HAMA评分明显低于对照组

WMS评分明显高于对照组

炎症因子水平明显低于对照组

差异均有统计学意义（P <0.05）。观察组患者的总有效率为95.65%（66/69）

明显高于对照组的82.61%（57/69）

差异有统计学意义（P <0.05）。观察组患者的不良反应发生率为11.59%（8/69）

略高于对照组的7.25%（5/69）

但两组比较的差异无统计学意义（P>0.05）。结论:艾司西酞普兰联合多巴丝肼可有效改善帕金森病患者的临床症状

抑制机体炎症反应

修复受损神经

效果显著。

Abstract

OBJECTIVE: To explore the clinical effects of escitalopram combined with dopasin on patients with Parkinson’s disease and its effects on inflammatory factors. METHODS: Totally 138 patients with Parkinson‘s disease admitted into Jingzhou the First People’s Hospital from Apr. 2018 to Dec. 2019 were extracted to be divided into the control group and the observation group

with 69 cases in each group. The control group was treated with dopasizide

while the observation group received escitalopram on the basis of the control group. Hamilton depression scale（ HAMD）

unified Parkinson’s disease rating scale（ UPDRS）

Hamilton anxiety scale（ HAMA） and Wechsler memory scale（ WMS） scores

inflammation factor levels

clinical efficacy and adverse drug reactions of two groups were observed. RESULTS: HAMD

UPDRS and HAMA scores of the observation group were significantly lower than those of the control group

WMS scores were significantly higher than those of the control group

and inflammatory factors were significantly lower than those of the control group

the differences were statistically significant（ P <0. 05）. The total effective rate in the observation group was 95. 65%（ 66/69）

significantly higher than 82. 61%（ 57/69） in the control group

with statistically significant difference（ P < 0. 05）. The incidence of adverse drug reactions in the observation group was 11. 59%（ 8/69）

slightly higher than that in the control group 7. 25%（ 5/69）

yet the difference was not statistically significant（ P > 0. 05）. CONCLUSIONS: Escitalopram combined with dopamine can effectively improve the clinical symptoms of patients with Parkinson’s disease

inhibit the inflammatory response and repair damaged nerves.

关键词

艾司西酞普兰多巴丝肼帕金森病炎症因子

Keywords

EscitalopramDobazideParkinson’s diseaseInflammatory factors

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Reduced Glutathione Infusion on Inflammatory Response in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Effects of Budesonide for Inhalation on Ventilator Weaning Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Placental Permeability of Escitalopram Based on Human Placental Extracorporeal Circulation Perfusion Model

Efficacy of Xuanfei Tongluo Formula in the Treatment of Children with Mycoplasma Pneumoniae Pneumonia and Its Effects on Inflammatory Factors, sIgA, hBD2 and CAL

Effects of Doxepin Combined with Escitalopram on Levels of Glial Cell-Derived Neurotrophic Factor and 5-Hydroxytryptamine in Patients with Depression

Related Author

CHEN Chen

WANG Yang

ZHANG Xiangru

ZHU Bai

SUN Zhongmin

CHEN Tianjun

LYU Yuan

LIU Ruming

Related Institution

Dept.of Cardiology, the First Affiliated Hospital of Xi’an Jiaotong University

Dept.of Pharmacy, the First Affiliated Hospital of Xi’an Jiaotong University

Dept.of Respiratory,the First Affiliated Hospital,Xi’an Jiaotong University

Dept.of Pharmacy,the First affiliated Hospital,Xi’an Jiaotong University

Dept.of Clinical Pharmacy, the First Affiliated Hospital of Kunming Medical University

⁰